Docetaxel rechallenge significantly improved survival compared with cabazitaxel in certain men with metastatic ...

Doxetaxel recharge was associated with a 3.3-month benefit in OS and a 1.8-month improvement in time to subsequent treatment or death. Docetaxel rechallenge improved overall survival compared with ...

Docetaxel rechallenge was tied to improved overall survival compared with cabazitaxel in men with metastatic castration-resistant prostate cancer (mCRPC) who did not experience disease progression on ...

Primary Mediastinal Germ Cell Tumors: A Real-World Analysis of Clinical Characteristics, Treatment, and Survival Outcomes From Two Tertiary Cancer Centers in India Abiraterone acetate (AA) is approved ...

Experts project the diagnosis of over 300,000 prostate cancer cases in the United States in 2006, along with over 30,000 prostate cancer-related deaths. As such, prostate cancer remains the most ...